Announcements Trials
Browse Landscape Eligibility

Clinical Trials

2 trials
RecentStart dateEnrollment
Genes × Clear all

Phase

Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Lymphoma, AIDS-Related 1Lymphoma 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 2848Cisplatin 2837Carboplatin 2635Radiotherapy 2522Paclitaxel 2424Gemcitabine 2263pembrolizumab 2099Docetaxel 1978Bevacizumab 1966Fluorouracil 1660Capecitabine 1640Oxaliplatin 1551Dexamethasone 1417Nivolumab 1394Doxorubicin 1349Rituximab 1338Magnetic Resonance Spectroscopy 1229Etoposide 1198Irinotecan 1122Leucovorin 1096Drug Therapy 1062Cytarabine 1010Pemetrexed 944fludarabine 933Specimen Handling 875Vincristine 857Prednisone 851Lenalidomide 838Trastuzumab 837Cetuximab 831

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT00858793 2022-09-08

High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Terminated
5 enrolled
Lymphoid

Acquired Immunodeficiency Syndrome, Lymphoma, HIV Infections, Lymphoma, AIDS-Related

NCT03152448 2022-06-13

P-PROVE

Myriad Genetic Laboratories, Inc.

Terminated
1,511 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡